Spyre Therapeutics ($SYRE) Insider Trading & Smart Money Activity
Spyre Therapeutics, Inc. ($SYRE) has 9 insider trades, 2 13F position changes and 2 analyst ratings on file. In the last 12 months on the open market, no insider bought and 5 insiders sold ($407.93M), net -$407.93M.
- Insider buyers (12 mo)
- 0
- Insider sellers (12 mo)
- 5
- Net insider $ (12 mo)
- -$407.93M
- Congress trades (12 mo)
- 0
- 13F moves on file
- 2
- Analyst ratings on file
- 2
SYRE insider buying and selling by quarter
| Quarter | Insider buys | Insider sales | Congress buys / sales | 13F added / cut |
|---|---|---|---|---|
| Q1 2026 | 0 | 0 | 0 / 0 | 0 / 0 |
| Q2 2026 | 0 | 2 · $401.66M | 0 / 0 | 0 / 2 |
| Q3 2026 | 0 | 1 · $1.57M | 0 / 0 | 0 / 0 |
| Q4 2026 | 0 | 3 · $4.70M | 0 / 0 | 0 / 0 |
Insider buys and sales count open-market trades only (Form 4 codes P and S). Grants, option exercises and tax withholding are left out.
All SYRE insider, congress, 13F and analyst activity
| Date | Source | Who | Action | Shares | Value / amount | ΔOwn | 1W | 1M | 6M | Filing | Story |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Insider | Turtle CameronChief Executive Officer | Sell (Open-market sale) 10b5-1 | 15K sh | $1.38M | -11.2% | — | |||||
| Insider | King-Jones HeidyChief Legal Officer and Corporate Secretary | Sell (Open-market sale) 10b5-1 | 28.93K sh | $2.63M | -11.2% | — | |||||
| Insider | Burrows Scott LChief Financial Officer | Sell (Open-market sale) 10b5-1 | 7.50K sh | $688.76K | -11.2% | — | |||||
| Insider | Burrows Scott LChief Financial Officer | Sell (Open-market sale) 10b5-1 | 17.50K sh | $1.57M | -9.2% | — | |||||
| Insider | Scott BurrowsChief Financial Officer | Sell (Option exercise) | 15K sh | -2.3% | +12.8% | Read | |||||
| Insider | Scott BurrowsChief Financial Officer | Buy (Option exercise) | 15K sh | $217.50K | -2.3% | +12.8% | Read | ||||
| Insider | Fairmount Funds Management LLC | Sell (Open-market sale) | 4.68M sh | $399.66M | -8.5% | +3.0% | Read | ||||
| Insider | Fairmount Funds Management LLC | Buy (Conversion) | 666.68K sh | -8.5% | +3.0% | Read | |||||
| Analyst | Deutsche Bank | Reiterates to buy | PT $135 | -8.5% | +3.0% | Read | |||||
| Insider | Henderson Michael Thomas | Sell (Open-market sale) 10b5-1 | 20K sh | $2M | -10.1% | -1.1% | Read | ||||
| Analyst | BTIG | Reiterates to buy | PT $112 | +16.4% | +12.8% | Read | |||||
| 13F | Driehaus Capital Management | Reduced | -91.64K sh | $225.47M | -1.2% | +11.6% | Read | ||||
| 13F | Driehaus Capital Management | Reduced | -91.64K sh | $247.77M | -1.2% | +11.6% | Read |
1W / 1M / 6M = how SYRE moved from the trade or filing date.
Insider trading in SYRE: who is buying and selling
| Insider | Role | Trades | Open-market net | Shares held | Last trade |
|---|---|---|---|---|---|
| Burrows Scott L | Chief Financial Officer | 2 | -$2.26M | Oct 1, 2026 | |
| Turtle Cameron | Chief Executive Officer | 1 | -$1.38M | Oct 1, 2026 | |
| King-Jones Heidy | Chief Legal Officer and Corporate Secretary | 1 | -$2.63M | Oct 1, 2026 | |
| Scott Burrows | Chief Financial Officer | 2 | — | Jun 25, 2026 | |
| Fairmount Funds Management LLC | 2 | -$399.66M | Jun 23, 2026 | ||
| Henderson Michael Thomas | 1 | -$2M | Jun 22, 2026 |
Institutions moving SYRE (13F)
Analyst ratings on SYRE
Frequently asked questions
Are SYRE insiders buying or selling?
Over the last 12 months 0 insiders made 0 open-market purchases worth $0 and 5 insiders made 6 open-market sales worth $407.93M, a net -$407.93M.
What is the latest insider trade in SYRE?
Turtle Cameron, Chief Executive Officer filed a sell (open-market sale) of 15K sh worth $1.38M on Oct 1, 2026.
Which institutions changed their SYRE positions?
Recent 13F filers moving the stock include Driehaus Capital Management.
Other biotechnology stocks
Data comes from public SEC Form 4 and 13F filings and STOCK Act disclosures. Dates are the trade or filing date reported. This page is for research only and is not investment advice.
Get a text when insiders, Congress or big funds trade a stock.
Free. Reply STOP anytime.